Manidipine Eg

Manidipine, the active ingredient in Manidipine Eg, is a calcium channel blocker presented as an oral tablet for oral use. It treats hypertension by lowering elevated blood pressure in adult patients. GNH USA supplies Manidipine Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manidipine is used in the management of hypertension, a condition characterized by chronically elevated arterial pressure. - Hypertension: reduces elevated blood pressure in patients with essential hypertension, helping to achieve target blood pressure levels. - Isolated systolic hypertension: lowers systolic pressure in older adults where systolic elevation predominates. - Secondary hypertension (as adjunct therapy): may be added to other antihypertensive agents when blood pressure remains uncontrolled.

Manidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: sensation of warmth and redness, usually short‑lived. - Peripheral edema: swelling of ankles or feet due to fluid accumulation. - Dizziness: feeling light‑headed, especially after standing.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Myocardial infarction: rare occurrence of heart attack. - Arrhythmias: abnormal heart rhythms, including bradycardia. - Allergic reactions: rash, pruritus, or anaphylaxis in susceptible individuals.

Before initiating therapy with Manidipine, several safety considerations should be observed. - Monitor blood pressure: ensure adequate control and avoid excessive hypotension. - Assess renal function: dose adjustment may be needed in severe impairment. - Use caution in the elderly: increased sensitivity to blood‑pressure lowering effects. - Avoid abrupt discontinuation: may lead to rebound hypertension. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Manidipine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other calcium channel blockers: additive hypotensive effect may cause severe low blood pressure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase plasma concentrations, raising risk of toxicity. - Potent CYP3A4 inducers (e.g., rifampicin, carbamazepine): reduce drug exposure, diminishing antihypertensive effect.

Moderate Interactions (Monitor Closely): - Beta‑blockers: combined use may enhance bradycardia and AV‑block. - Diuretics: concurrent therapy can increase risk of electrolyte disturbances and volume depletion.